bevacizumab + capecitabine + letrozole + vinorelbine

This is a combination regimen consisting of four distinct anticancer agents, each with a different mechanism of action: - **Bevacizumab** is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis and reducing tumor blood supply. - **Capecitabine** is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body, inhibiting DNA synthesis and function as an antimetabolite. - **Letrozole** is an aromatase inhibitor that suppresses estrogen biosynthesis, used primarily in hormone receptor-positive breast cancer. - **Vinorelbine** is a vinca alkaloid chemotherapy agent that disrupts microtubule formation during cell division, leading to apoptosis. This combination targets multiple pathways involved in tumor growth and survival. It may be considered for investigational or off-label use in advanced or metastatic cancers where multi-modal therapy could provide synergistic effects. Each component has established roles in various solid tumors such as breast cancer, colorectal cancer, lung cancer, and ovarian cancer[2][3][5][7][10].